The company has a market cap of over Rs 500 crore and reported excellent numbers in its quarterly results and annual results.

According to the quarterly results, the net sales increased by 12 per cent to Rs 41.89 crore, and operating profit increased by 336 per cent to Rs 3.91 crore and the net profit increased by 120 per cent to Rs1.03 crore in Q1FY24 over Q1FY23.

The company reported positive numbers in its quarterly results and annual results. In FY23, the company ex-traded bonus shares in the ratio of 2:1 and stock split from a face value of Rs 10 to a face value of Rs 1.

According to the quarterly results, the company reported a net profit in the first quarter of the fiscal year 2024 at Rs 1.18 crore, up more than 100 per cent from the corresponding period of the previous fiscal. The company posted a net profit of Rs 0.58 crore in Q1FY23. The company's total income in the June 2023 quarter increased to Rs 56.3 crore from Rs 55.9 crore a year ago period, up 0.72 per cent.

According to the annual results, the net sales increased by 45.43 per cent to Rs 27.3 crore, operating profit increased by 176.5 per cent to Rs 6.09 crore and net profit increased by 271.6 per cent to Rs 2.75 crore in FY23 compared to FY22.

Commenting on the expansion, Managing Director, Mr Rajinder Mittal said: “We are extremely delighted to announce the commissioning of our brownfield expansion at Bhatinda. This expansion has propelled BCL to become one of the largest grain-based distilleries in India. We are committed and proud to be a part of promoting the government’s initiatives on Bio-Fuels in India.”

The company has a market cap of over Rs 4,000 crore. According to its quarterly results (Q1FY24) and annual results (FY23), the company reported positive numbers and has delivered good profit growth of 18.30 per cent CAGR over the last 5 years

The stock has an ROE of 42 per cent and a ROCE of 32.1 per cent with a 5-year stock price CAGR of 40 per cent. An ace investor, Ashish Kacholia owns 2.15 per cent skate in the company as of June 2023.

According to the quarterly results, the net sales decreased by 9 per cent to Rs 10.18 crore while net profit skyrocketed to 787 per cent to Rs 0.71 crore in Q1FY24 compared to Q1FY23.

The marketing approval for Enoxaparin in Saudi Arabia is anticipated to pave the way for similar authorizations in other GCC and MENA countries. This anticoagulant holds significance in treating cardiovascular diseases, a notable health concern in Saudi Arabia, and is expected to contribute to the burgeoning global Enoxaparin market.